CBL is frequently altered in lung cancers: Its relationship to mutations in met and EGFR tyrosine kinases

PLoS ONE

Volumn 5, Issue 1, 2010, Pages

  Tan, Yi Hung Carol ^a   Krishnaswamy, Soundararajan ^b   Nandi, Suvobroto ^b   Kanteti, Rajani ^b   Vora, Sapana ^b   Onel, Kenan ^b   Hasina, Rifat ^b   Lo, Fang Yi ^a   El Hashani, Essam ^b   Cervantes, Gustavo ^b   Robinson, Matthew ^b   Kales, Stephen C ^c   Lipkowitz, Stanley ^c   Karrison, Theodore ^d   Sattler, Martin ^e   Vokes, Everett E ^b   Wang, Yi Ching ^f   Salgia, Ravi ^b  

^a NATIONAL TAIWAN NORMAL UNIVERSITY   (Taiwan)

^b University of Chicago   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CBL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GENOMIC DNA; K RAS PROTEIN; PROTEIN P53; SCATTER FACTOR RECEPTOR;

ARTICLE; CELL MOTILITY; CELL VIABILITY; CORRELATION ANALYSIS; GENE LOCUS; GENE MUTATION; GENETIC VARIABILITY; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MISSENSE MUTATION; MUTATION RATE; SOMATIC MUTATION;

BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 11; DNA PRIMERS; FLOW CYTOMETRY; HUMANS; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE; PARAFFIN EMBEDDING; PROTO-ONCOGENE PROTEINS C-CBL; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, GROWTH FACTOR;

EID: 77952479240     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008972     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
2. Langdon WY, Hyland CD, Grumont RJ, Morse HC 3rd (1989) The c-cbl protooncogene is preferentially expressed in thymus and testis tissue and encodes a nuclear protein. J Virol 63: 5420-5424.
3. Swaminathan G, Tsygankov AY (2006) The Cbl family proteins: ring leaders in regulation of cell signaling. J Cell Physiol 209: 21-43.
4. Nau MM, Lipkowitz S (2003) Comparative genomic organization of the cbl genes. Gene 308: 103-113.
5. Kozlov G, Peschard P, Zimmerman B, Lin T, Moldoveanu T, et al. (2007) Structural basis for UBA-mediated dimerization of c-Cbl ubiquitin ligase. J Biol Chem 282: 27547-27555.
6. Waterman H, Levkowitz G, Alroy I, Yarden Y (1999) The RING finger of c-Cbl mediates desensitization of the epidermal growth factor receptor. J Biol Chem 274: 22151-22154.
7. Thien CB, Langdon WY (1997) EGF receptor binding and transformation by vcbl is ablated by the introduction of a loss-of-function mutation from the Caenorhabditis elegans sli-1 gene. Oncogene 14: 2239-2249.
8. Miyake S, Mullane-Robinson KP, Lill NL, Douillard P, Band H (1999) Cblmediated negative regulation of platelet-derived growth factor receptordependent cell proliferation. A critical role for Cbl tyrosine kinase-binding domain. J Biol Chem 274: 16619-16628.
9. Lill NL, Douillard P, Awwad RA, Ota S, Lupher ML Jr, et al. (2000) The evolutionarily conserved N-terminal region of Cbl is sufficient to enhance downregulation of the epidermal growth factor receptor. J Biol Chem 275: 367-377.
10. Meng W, Sawasdikosol S, Burakoff SJ, Eck MJ (1999) Structure of the aminoterminal domain of Cbl complexed to its binding site on ZAP-70 kinase. Nature 398: 84-90.
11. Peschard P, Fournier TM, Lamorte L, Naujokas MA, Band H, et al. (2001) Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell 8: 995-1004.
12. Zheng N, Wang P, Jeffrey PD, Pavletich NP (2000) Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell 102: 533-539.
13. Fukazawa T, Miyake S, Band V, Band H (1996) Tyrosine phosphorylation of Cbl upon epidermal growth factor (EGF) stimulation and its association with EGF receptor and downstream signaling proteins. J Biol Chem 271: 14554-14559.
14. Meisner H, Czech MP (1995) Coupling of the proto-oncogene product c-Cbl to the epidermal growth factor receptor. J Biol Chem 270: 25332-25335.
15. Ettenberg SA, Keane MM, Nau MM, Frankel M, Wang LM, et al. (1999) cbl-b inhibits epidermal growth factor receptor signaling. Oncogene 18: 1855-1866.
16. Bao J, Alroy I, Waterman H, Schejter ED, Brodie C, et al. (2000) Threonine phosphorylation diverts internalized epidermal growth factor receptors from a degradative pathway to the recycling endosome. J Biol Chem 275: 26178-26186.
17. Burke P, Schooler K, Wiley HS (2001) Regulation of epidermal growth factor receptor signaling by endocytosis and intracellular trafficking. Mol Biol Cell 12: 1897-1910.
18. Clague MJ, Urbe S (2001) The interface of receptor trafficking and signalling. J Cell Sci 114: 3075-3081.
19. Shtiegman K, Kochupurakkal BS, Zwang Y, Pines G, Starr A, et al. (2007) Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. Oncogene 26: 6968-6978.
20. Sargin B, Choudhary C, Crosetto N, Schmidt MH, Grundler R, et al. (2007) Flt3-dependent transformation by inactivating c-Cbl mutations in AML. Blood 110: 1004-1012.
21. Bean J, Brennan C, Shih JY, Riely G, Viale A, et al. (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104: 20932-20937.
22. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
23. Caligiuri MA, Briesewitz R, Yu J, Wang L, Wei M, et al. (2007) Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. Blood 110: 1022-1024.
24. Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, et al. (2009) Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 113: 6182-6192.
25. Dunbar AJ, Gondek LP, O'Keefe CL, Makishima H, Rataul MS, et al. (2008) 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res 68: 10349-10357.
26. Sanada M, Suzuki T, Shih LY, Otsu M, Kato M, et al. (2009) Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 460: 904-908.
27. Reindl C, Quentmeier H, Petropoulos K, Greif PA, Benthaus T, et al. (2009) CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. Clin Cancer Res 15: 2238-2247.
28. Thien CB, Langdon WY (2001) Cbl: many adaptations to regulate protein tyrosine kinases. Nat Rev Mol Cell Biol 2: 294-307.
29. Reindl C, Quentmeier H, Petropoulos K, Greif PA, Benthaus T, et al. (2009) CBL Exon 8/9 Mutants Activate the FLT3 Pathway and Cluster in Core Binding Factor/11q Deletion Acute Myeloid Leukemia/Myelodysplastic Syndrome Subtypes. Clin Cancer Res 15: 2238-2247.
30. Abidoye O, Murukurthy N, Salgia R (2007) Review of clinic trials: agents targeting c-Met. Rev Recent Clin Trials 2: 143-147.
31. Krishnaswamy S, Kanteti R, Duke-Cohan JS, Loganathan S, Liu W, et al. (2009) Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res 15: 5714-5723.
32. Herrmann J, Lerman LO, Lerman A (2007) Ubiquitin and ubiquitin-like proteins in protein regulation. Circ Res 100: 1276-1291.
33. Wang Y, Werz C, Xu D, Chen Z, Li Y, et al. (2008) Drosophila cbl is essential for control of cell death and cell differentiation during eye development. PLoS One 3: e1447.
34. Hirsch DS, Shen Y, Wu WJ (2006) Growth and motility inhibition of breast cancer cells by epidermal growth factor receptor degradation is correlated with inactivation of Cdc42. Cancer Res 66: 3523-3530.
35. Rao N, Dodge I, Band H (2002) The Cbl family of ubiquitin ligases: critical negative regulators of tyrosine kinase signaling in the immune system. J Leukoc Biol 71: 753-763.
36. Naramura M, Kole HK, Hu RJ, Gu H (1998) Altered thymic positive selection and intracellular signals in Cbl-deficient mice. Proc Natl Acad Sci U S A 95: 15547-15552.
37. Murphy MA, Schnall RG, Venter DJ, Barnett L, Bertoncello I, et al. (1998) Tissue hyperplasia and enhanced T-cell signalling via ZAP-70 in c-Cbl-deficient mice. Mol Cell Biol 18: 4872-4882.
38. Onozato R, Kosaka T, Kuwano H, Sekido Y, Yatabe Y, et al. (2009) Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol 4: 5-11.
39. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075.
40. Tan Y-H, Salgia R, Hsieh-Li H-M, Wang Y-C (2009) Novel Mutations in c-Cbl Ubiquitin Ligase Gene in Taiwanese Lung Cancer. BioFormosa 44: 1-10.
41. Higgins RS, Lewis C, Warren WH (2003) Lung cancer in African Americans. Ann Thorac Surg 76: S1363-1366.